Ovid Therapeutics Inc. (OVID) — 10-Q Filings

10-Q Filings (6)

• Ovid's Q3 Loss Narrows, Cash Infusion Boosts Outlook — Nov 12, 2025 Risk: medium
  Ovid Therapeutics Inc. reported a net loss of $12.2 million for the three months ended September 30, 2025, and a net loss of $27.1 million for the nine months e
• Ovid Therapeutics Faces Going Concern Doubt Amidst Widening Losses — Aug 13, 2025 Risk: high
  Ovid Therapeutics Inc. reported a net loss of $4.7 million for the three months ended June 30, 2025, a significant decline from the net income of $8.5 million i
• Ovid Therapeutics Files Q1 2025 10-Q — May 13, 2025 Risk: low
  Ovid Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including co
• Ovid Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Ovid Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and operational updates. Specific fin
• Ovid Therapeutics Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Ovid Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business opera
• Ovid Therapeutics Files Q1 2024 Report — May 14, 2024 Risk: medium
  Ovid Therapeutics Inc. filed its quarterly report for the period ended March 31, 2024. The company is registered in Delaware and its common stock trades on the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX